bio-rad laboratories inc. - BIO

BIO

Close Chg Chg %
292.32 4.51 1.54%

Open Market

296.83

+4.51 (1.54%)

Volume: 70.86K

Last Updated:

Apr 15, 2026, 3:26 PM EDT

Company Overview: bio-rad laboratories inc. - BIO

BIO Key Data

Open

$293.21

Day Range

292.15 - 297.50

52 Week Range

211.69 - 343.12

Market Cap

$7.89B

Shares Outstanding

26.99M

Public Float

18.09M

Beta

1.16

Rev. Per Employee

N/A

P/E Ratio

10.49

EPS

$27.95

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

313.77K

 

BIO Performance

1 Week
 
4.65%
 
1 Month
 
11.20%
 
3 Months
 
-6.79%
 
1 Year
 
22.69%
 
5 Years
 
-53.33%
 

BIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About bio-rad laboratories inc. - BIO

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

BIO At a Glance

Bio-Rad Laboratories, Inc.
1000 Alfred Nobel Drive
Hercules, California 94547
Phone 1-510-724-7000 Revenue 2.58B
Industry Medical Specialties Net Income 759.90M
Sector Health Technology 2025 Sales Growth 0.651%
Fiscal Year-end 12 / 2026 Employees 7,450
View SEC Filings

BIO Valuation

P/E Current 10.491
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 10.878
Price to Sales Ratio 3.20
Price to Book Ratio 1.097
Price to Cash Flow Ratio 15.53
Enterprise Value to EBITDA 17.197
Enterprise Value to Sales 3.139
Total Debt to Enterprise Value 0.171

BIO Efficiency

Revenue/Employee 346,738.255
Income Per Employee 102,000.00
Receivables Turnover 5.467
Total Asset Turnover 0.259

BIO Liquidity

Current Ratio 5.621
Quick Ratio 4.189
Cash Ratio 2.984

BIO Profitability

Gross Margin 52.013
Operating Margin 10.301
Pretax Margin 38.537
Net Margin 29.417
Return on Assets 7.622
Return on Equity 10.838
Return on Total Capital 8.597
Return on Invested Capital 9.099

BIO Capital Structure

Total Debt to Total Equity 18.586
Total Debt to Total Capital 15.673
Total Debt to Total Assets 13.098
Long-Term Debt to Equity 18.077
Long-Term Debt to Total Capital 15.244
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-rad Laboratories Inc. - BIO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.80B 2.67B 2.57B 2.58B
Sales Growth
-4.12% -4.67% -3.92% +0.65%
Cost of Goods Sold (COGS) incl D&A
1.23B 1.24B 1.19B 1.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
177.20M 192.40M 192.80M 205.40M
Depreciation
152.30M 168.60M 171.60M 181.60M
Amortization of Intangibles
24.90M 23.80M 21.20M 23.80M
COGS Growth
-1.84% +0.49% -4.22% +4.38%
Gross Income
1.57B 1.43B 1.38B 1.34B
Gross Income Growth
-5.84% -8.74% -3.66% -2.56%
Gross Profit Margin
+55.97% +53.58% +53.73% +52.01%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.09B 1.05B 1.07B 1.08B
Research & Development
256.79M 226.93M 253.90M 257.60M
Other SG&A
832.33M 820.62M 814.00M 819.90M
SGA Growth
-2.04% -3.82% +1.94% +0.90%
Other Operating Expense
- - - -
-
Unusual Expense
5.21B 1.30B 2.70B (681.50M)
EBIT after Unusual Expense
(4.73B) (911.95M) (2.39B) 947.60M
Non Operating Income/Expense
62.78M 111.29M 94.20M 96.90M
Non-Operating Interest Income
58.00M 100.90M 82.00M 95.50M
Equity in Earnings of Affiliates
- - - 7.40M
-
Interest Expense
38.11M 49.44M 48.90M 49.00M
Interest Expense Growth
+2,357.38% +29.71% -1.09% +0.20%
Gross Interest Expense
38.11M 49.44M 48.90M 49.00M
Interest Capitalized
- - - -
-
Pretax Income
(4.70B) (850.10M) (2.34B) 995.50M
Pretax Income Growth
-186.51% +81.93% -175.55% +142.50%
Pretax Margin
-167.87% -31.82% -91.27% +38.54%
Income Tax
(1.08B) (212.78M) (498.30M) 235.60M
Income Tax - Current - Domestic
140.76M 85.80M 95.00M 45.30M
Income Tax - Current - Foreign
24.10M 17.40M 28.50M 17.70M
Income Tax - Deferred - Domestic
(1.20B) (331.18M) (642.30M) 150.30M
Income Tax - Deferred - Foreign
(36.70M) 15.20M 20.50M 22.30M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - 7.40M
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.63B) (637.32M) (1.84B) 759.90M
Minority Interest Expense
- - - -
-
Net Income
(3.63B) (637.32M) (1.84B) 759.90M
Net Income Growth
-185.44% +82.43% -189.37% +141.20%
Net Margin Growth
-129.45% -23.86% -71.86% +29.42%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.63B) (637.32M) (1.84B) 759.90M
Preferred Dividends
- - - -
-
Net Income Available to Common
(3.63B) (637.32M) (1.84B) 759.90M
EPS (Basic)
-121.7907 -21.8194 -65.3647 27.8729
EPS (Basic) Growth
-185.57% +82.08% -199.57% +142.64%
Basic Shares Outstanding
29.79M 29.21M 28.21M 27.26M
EPS (Diluted)
-121.7907 -21.8194 -65.3647 27.8546
EPS (Diluted) Growth
-186.65% +82.08% -199.57% +142.61%
Diluted Shares Outstanding
29.79M 29.21M 28.21M 27.28M
EBITDA
656.52M 576.20M 503.80M 471.50M
EBITDA Growth
-9.69% -12.23% -12.56% -6.41%
EBITDA Margin
+23.43% +21.57% +19.63% +18.25%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 333.75
Number of Ratings 7 Current Quarters Estimate 2.472
FY Report Date 06 / 2026 Current Year's Estimate 10.29
Last Quarter’s Earnings 1.95 Median PE on CY Estimate N/A
Year Ago Earnings 9.92 Next Fiscal Year Estimate 11.581
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 2.47 2.65 10.29 11.58
High Estimates 2.54 2.76 10.55 11.95
Low Estimate 2.43 2.47 10.11 10.88
Coefficient of Variance 2.01 4.80 1.80 4.33

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 3 3
OVERWEIGHT 0 0 1
HOLD 5 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Bio-Rad Laboratories Inc. in the News